Prime Medicine (PRME) Research & Development (2021 - 2025)
Historic Research & Development for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to $44.0 million.
- Prime Medicine's Research & Development rose 904.81% to $44.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $160.0 million, marking a year-over-year decrease of 160.66%. This contributed to the annual value of $155.3 million for FY2024, which is 499.24% up from last year.
- As of Q3 2025, Prime Medicine's Research & Development stood at $44.0 million, which was up 904.81% from $41.4 million recorded in Q2 2025.
- In the past 5 years, Prime Medicine's Research & Development ranged from a high of $52.9 million in Q4 2021 and a low of $7.4 million during Q3 2021
- Moreover, its 5-year median value for Research & Development was $37.8 million (2024), whereas its average is $33.9 million.
- The largest annual percentage gain for Prime Medicine's Research & Development in the last 5 years was 23847.3% (2022), contrasted with its biggest fall of 4505.28% (2022).
- Over the past 5 years, Prime Medicine's Research & Development (Quarter) stood at $52.9 million in 2021, then plummeted by 45.05% to $29.1 million in 2022, then skyrocketed by 42.66% to $41.5 million in 2023, then fell by 17.74% to $34.1 million in 2024, then increased by 28.99% to $44.0 million in 2025.
- Its Research & Development stands at $44.0 million for Q3 2025, versus $41.4 million for Q2 2025 and $40.6 million for Q1 2025.